ReviewMolecules (Basel, Switzerland)2015
The Potential Use of Natural and Structural Analogues of Antimicrobial Peptides in the Fight against Neglected Tropical Diseases.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Microbe-Derived Antimicrobial Peptides: Immunomodulation and Gut Microbiota Homeostasis.Microorganisms · 2026Review
- The Snakin Family of Antimicrobial Peptides: Promising Alternatives to Conventional Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.Microbiology (Reading, England) · 2026Article
- A Comprehensive Overview of Antimicrobial Peptides: Broad-Spectrum Activity, Computational Approaches, and Applications.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial Plant Peptides: Structure, Classification, Mechanism and Therapeutic Potential.Current topics in medicinal chemistry · 2025Review
- Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Peptide Dimerization as a Strategy for the Development of Antileishmanial Compounds.Molecules (Basel, Switzerland) · 2024Article
- Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule.Antibiotics (Basel, Switzerland) · 2024Article
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Why the SAFE-Pathogens (Basel, Switzerland) · 2023Review
- Development of New Leishmanicidal Compounds via Bioconjugation of Antimicrobial Peptides and Antileishmanial Guanidines.ACS omega · 2023Article
- Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Anticancer activities of natural antimicrobial peptides from animals.Frontiers in microbiology · 2023Review
- Natural and Synthetic Halogenated Amino Acids-Structural and Bioactive Features in Antimicrobial Peptides and Peptidomimetics.Molecules (Basel, Switzerland) · 2021Review
- Antimicrobial peptides: mechanism of action, activity and clinical potential.Military Medical Research · 2021Review
- Antimicrobial Peptides in Farm Animals: An Updated Review on Its Diversity, Function, Modes of Action and Therapeutic Prospects.Veterinary sciences · 2020Review
- Viruses of protozoan parasites and viral therapy: Is the time now right?Virology journal · 2020Review
- Antimicrobial and Antibiofilm Peptides.Biomolecules · 2020Review
- Natural Occurrence in Venomous Arthropods of Antimicrobial Peptides Active against Protozoan Parasites.Toxins · 2019Review
- Antimicrobial Peptides: the Achilles' Heel of Antibiotic Resistance?Probiotics and antimicrobial proteins · 2019Review
Corrections and comments
- Erratum issuedCorrection: Lewies, A., et al. The Potential Use of Natural and Structural Analogues of Antimicrobial Peptides in the Fight against Neglected Tropical Diseases. Molecules 2015, 20, 15392-15433.2015 · Angélique, Lewies; Frederik, Wentzel Johannes; Garmi, Jacobs and Hester, Du Plessis Lissinda [Corrected to Lewies, Angélique; Wentzel, Johannes F; Jacobs, Garmi and Du Plessis, Lissinda H]
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, research into the development of new antimicrobial agents has been driven by the increase in resistance to traditional antibiotics and Emerging Infectious Diseases. Antimicrobial peptides (AMPs) are promising candidates as alternatives to current antibiotics in the treatment and prevention of microbial infections. AMPs are produced by all known living species, displaying direct antimicrobial killing activity and playing an important role in innate immunity. To date, more than 2000 AMPs have been discovered and many of these exhibit broad-spectrum antibacterial, antiviral and anti-parasitic activity. Neglected tropical diseases (NTDs) are caused by a variety of pathogens and are particularly wide-spread in low-income and developing regions of the world. Alternative, cost effective treatments are desperately needed to effectively battle these medically diverse diseases. AMPs have been shown to be effective against a variety of NTDs, including African trypanosomes, leishmaniosis and Chagas disease, trachoma and leprosy. In this review, the potential of selected AMPs to successfully treat a variety of NTD infections will be critically evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.